+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gilead Sciences Inc - logo

Founded in 1987 Gilead Sciences is a biopharmaceutical company focused on developing innovative treatments for life threatening illnesses. Their areas of research include HIV/AIDs, Liver Diseases, Hematology, Oncology, Cardiovascular and Respiratory disease. Gilead Sciences is based in California, USA and their product portfolio consists of well-known treatments like Atripla, Sovaldi, Zydelig, Viread and many more.

From
Esophageal Cancer Global Market Report 2024 - Product Thumbnail Image

Esophageal Cancer Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
Chronic Spontaneous Urticaria - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Spontaneous Urticaria - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Rheumatoid Arthritis Drugs Global Market Report 2024 - Product Thumbnail Image

Rheumatoid Arthritis Drugs Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
Ayvakit Patent, Sales & Clinical Trials Insight 2028 - Product Thumbnail Image

Ayvakit Patent, Sales & Clinical Trials Insight 2028

  • Report
  • October 2021
  • 85 Pages
  • Global
From
From
Pharmaceutical Fluid Handling Global Market Report 2024 - Product Thumbnail Image

Pharmaceutical Fluid Handling Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034

  • Report
  • March 2024
  • 200 Pages
  • Global
From
Ulcerative Colitis - Pipeline Insight, 2024 - Product Thumbnail Image

Ulcerative Colitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
From
Farnesoid X Receptor (FXR) Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Farnesoid X Receptor (FXR) Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator